/CDXI
CDXI Stock - Cardax, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CDXI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-13.76
52W High$0.00
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|
| Revenue | $538,946 | $710,949 | $1.51M | $610,323 | $35,258 |
| Gross Profit | $342,816 | $365,556 | $811,023 | $335,616 | $20,678 |
| Gross Margin | 63.6% | 51.4% | 53.7% | 55.0% | 58.6% |
| Operating Income | $-3,062,636 | $-4,077,103 | $-4,022,495 | $-2,002,270 | $-1,830,224 |
| Net Income | $-5,055,507 | $-5,093,037 | $-4,024,222 | $-1,985,234 | $-1,783,705 |
| Net Margin | -938.0% | -716.4% | -266.4% | -325.3% | -5059.0% |
| EPS | $-6.79 | $-8.40 | $-6.32 | $-3.97 | $-4.68 |
Company Overview
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CDXIBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-1.74
Q2 2021
EPS Surprise History
Q3 19
No data
Q4 19
No data
Q4 19
No data
Q2 20
No data
Q3 20
No data
Q4 20
No data
Q4 20
No data
Q2 21
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2021 | May 14, 2021 | — | $-1.74 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-1.79 | — | — |
Q4 2020 | Nov 13, 2020 | — | $-1.79 | — | — |
Q3 2020 | Aug 14, 2020 | — | $-2.26 | — | — |
Q2 2020 | May 15, 2020 | — | $-1.43 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-2.10 | — | — |
Q4 2019 | Nov 14, 2019 | — | $-2.00 | — | — |
Q3 2019 | Aug 14, 2019 | — | $-2.00 | — | — |
Q2 2019 | May 15, 2019 | — | $-2.00 | — | — |
Q1 2019 | Mar 28, 2019 | — | $-2.00 | — | — |
Q4 2018 | Nov 13, 2018 | — | $-2.00 | — | — |
Q3 2018 | Aug 13, 2018 | — | $-2.00 | — | — |
Q2 2018 | May 9, 2018 | — | $-2.00 | — | — |
Q1 2018 | Mar 27, 2018 | — | $-2.00 | — | — |
Q4 2017 | Nov 14, 2017 | — | $-0.00 | — | — |
Q3 2017 | Aug 11, 2017 | — | $-0.00 | — | — |
Q2 2017 | May 15, 2017 | — | $-2.00 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.00 | — | — |
Q4 2016 | Nov 14, 2016 | — | $-2.00 | — | — |
Q3 2016 | Aug 15, 2016 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about CDXI
What is CDXI's current stock price?
Cardax, Inc. (CDXI) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for CDXI?
No analyst price targets are currently available for this stock.
What sector is Cardax, Inc. in?
Cardax, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is CDXI's market cap?
Cardax, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does CDXI pay dividends?
No, Cardax, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorELOX
Eloxx Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
LGBI
Cannabiz Mobile, Inc.
$0.00
Mkt Cap: $0.0B
MDVLQ
MedAvail Holdings, Inc.
$0.00
Mkt Cap: $0.0B
MICRD
Micron Solutions, Inc.
$0.00
Mkt Cap: $0.0B
MODC
Modern Technology Corp.
$0.00
Mkt Cap: $0.0B
MTST
MetaStat, Inc.
$0.00
Mkt Cap: $0.0B
NBRVF
Nabriva Therapeutics plc
$0.00
Mkt Cap: $0.0B
NEXI
NexImmune, Inc.
$0.00
Mkt Cap: $0.0B
ONCSQ
OncoSec Medical Incorporated
$0.00
Mkt Cap: $0.0B
VRCI
Verde Science, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to CDXI for comparison